DS-8201a + T-DM1
Phase 3Active 0 watching 0 views this weekπ Rising
77
Development Stage
β
Pre-clinicalβ
Phase 1β
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-Positive Primary Breast Cancer
Conditions
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Trial Timeline
Dec 4, 2020 β Dec 31, 2030
NCT ID
NCT04622319About DS-8201a + T-DM1
DS-8201a + T-DM1 is a phase 3 stage product being developed by Daiichi Sankyo for HER2-Positive Primary Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04622319. Target conditions include HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04622319 | Phase 3 | Active |
Competing Products
20 competing products in HER2-Positive Primary Breast Cancer